Distribution of FLT3-ITD, D835, and transcript expression by FAB morphological and cytogenetics subgroup in AML
. | Distribution, n (%) . | . | FLT3* expression (n) ITD/D835- . | |
|---|---|---|---|---|
. | FLT3 ITD+ . | FLT3 D835+ . | . | |
| Total AML† | 31 of 168 (18) | 10 of 164 (6) | 2.6 ± 1.4 (100) | |
| FAB | ||||
| M0 | 0 of 7 (0) | 0 of 6 (0) | 4 ± 1.5 (4) | |
| M1‡ | 7 of 35 (20) | 2 of 34 (6) | 2.2 ± 1.7 (16) | |
| M2, AMLI-ETO+ | 0 of 16 | 0 of 16 | 2.2 ± 1.3 (8) | |
| M2, AMLI-ETO- | 3 of 22 (14) | 1 of 22 (5) | 2.5 ± 1 (9) | |
| M4eo, CBFβ-MYH11+ | 1 of 15 (7) | 1 of 15 (7) | 2.1 ± 1.2 (8) | |
| M4, CBFβ-MYH11- | 7 of 25 (28) | 3 of 24 (13) | 2.5 ± 1.2 (11) | |
| M5‡ | 11 of 38 (30) | 3 of 38 (8) | 3.4 ± 0.9 (27) | |
| M6 | 1 of 3 (33) | 0 of 3 (0) | 1.7 (1) | |
| CG‡ | ||||
| Normal | 19 of 67 (28) | 2 of 65 (3) | 3.0 ± 1.2 (24) | |
| Complex, 5, 7 | 1 of 14 (7) | 1 of 12 (8) | 1.9 ± 1.9 (8) | |
| Abnormal§ | 2 of 22 (9) | 1 of 22 (5) | 2.9 ± 1.2 (12) | |
| AML1-ETO | 2 of 20 (10) | 0 of 20 (0) | 2.2 ± 1.2 (10) | |
| CBFβ-MYH1∥ | 1 of 17 (6) | 2 of 17 (12) | 2.1 ± 1.2 (8) | |
| DEK-CAN† | 6 of 9 (67) | 0 of 9 (0) | 2.9 ± 0.8 (2) | |
| PML-RARA† | 6 of 16 (38) | 1 of 16 (6) | 2.4 ± 1.8 (7) | |
| MLL† | ||||
| Dupl.¶ | 5 of 16 (31)¶ | 3 of 16 (19) | 2.1 ± 2.1 (6) | |
| Topo∥ | 3 of 8 (38) | 2 of 8 (25) | 2.9 ± 1 (2) | |
| Translocation | ||||
| Total | 2 of 40 (5) | 4 of 39 (10) | 2.8 ± 1.3 (22) | |
| Age | ||||
| Adults | 2 of 25 (8) | 2 of 25 (8) | ND | |
| Younger than 1 y# | 0 of 7 (0) | 1 of 7 (14) | ND | |
| 1-15 y** | 0 of 8 (0) | 1 of 7 (14) | ND | |
| MLL-partner | ||||
| AF6 | 0 of 8 (0) | 1 of 8 (13) | ND | |
| AF9 | 0 of 9 (0) | 1 of 9 (11) | ND | |
| AF10 | 0 of 7 (0) | 1 of 7 (14) | ND | |
| ELL | 0 of 6 (0) | 1 of 6 (17) | ND | |
| ENL | 1 of 3 (33) | 0 of 3 (0) | ND | |
| Other†† | 0 of 6 (0) | 0 of 5 (0) | ND | |
| t(11,17) | 1 of 1 (100) | 0 of 1 (0) | ND | |
. | Distribution, n (%) . | . | FLT3* expression (n) ITD/D835- . | |
|---|---|---|---|---|
. | FLT3 ITD+ . | FLT3 D835+ . | . | |
| Total AML† | 31 of 168 (18) | 10 of 164 (6) | 2.6 ± 1.4 (100) | |
| FAB | ||||
| M0 | 0 of 7 (0) | 0 of 6 (0) | 4 ± 1.5 (4) | |
| M1‡ | 7 of 35 (20) | 2 of 34 (6) | 2.2 ± 1.7 (16) | |
| M2, AMLI-ETO+ | 0 of 16 | 0 of 16 | 2.2 ± 1.3 (8) | |
| M2, AMLI-ETO- | 3 of 22 (14) | 1 of 22 (5) | 2.5 ± 1 (9) | |
| M4eo, CBFβ-MYH11+ | 1 of 15 (7) | 1 of 15 (7) | 2.1 ± 1.2 (8) | |
| M4, CBFβ-MYH11- | 7 of 25 (28) | 3 of 24 (13) | 2.5 ± 1.2 (11) | |
| M5‡ | 11 of 38 (30) | 3 of 38 (8) | 3.4 ± 0.9 (27) | |
| M6 | 1 of 3 (33) | 0 of 3 (0) | 1.7 (1) | |
| CG‡ | ||||
| Normal | 19 of 67 (28) | 2 of 65 (3) | 3.0 ± 1.2 (24) | |
| Complex, 5, 7 | 1 of 14 (7) | 1 of 12 (8) | 1.9 ± 1.9 (8) | |
| Abnormal§ | 2 of 22 (9) | 1 of 22 (5) | 2.9 ± 1.2 (12) | |
| AML1-ETO | 2 of 20 (10) | 0 of 20 (0) | 2.2 ± 1.2 (10) | |
| CBFβ-MYH1∥ | 1 of 17 (6) | 2 of 17 (12) | 2.1 ± 1.2 (8) | |
| DEK-CAN† | 6 of 9 (67) | 0 of 9 (0) | 2.9 ± 0.8 (2) | |
| PML-RARA† | 6 of 16 (38) | 1 of 16 (6) | 2.4 ± 1.8 (7) | |
| MLL† | ||||
| Dupl.¶ | 5 of 16 (31)¶ | 3 of 16 (19) | 2.1 ± 2.1 (6) | |
| Topo∥ | 3 of 8 (38) | 2 of 8 (25) | 2.9 ± 1 (2) | |
| Translocation | ||||
| Total | 2 of 40 (5) | 4 of 39 (10) | 2.8 ± 1.3 (22) | |
| Age | ||||
| Adults | 2 of 25 (8) | 2 of 25 (8) | ND | |
| Younger than 1 y# | 0 of 7 (0) | 1 of 7 (14) | ND | |
| 1-15 y** | 0 of 8 (0) | 1 of 7 (14) | ND | |
| MLL-partner | ||||
| AF6 | 0 of 8 (0) | 1 of 8 (13) | ND | |
| AF9 | 0 of 9 (0) | 1 of 9 (11) | ND | |
| AF10 | 0 of 7 (0) | 1 of 7 (14) | ND | |
| ELL | 0 of 6 (0) | 1 of 6 (17) | ND | |
| ENL | 1 of 3 (33) | 0 of 3 (0) | ND | |
| Other†† | 0 of 6 (0) | 0 of 5 (0) | ND | |
| t(11,17) | 1 of 1 (100) | 0 of 1 (0) | ND | |
ND indicates not done.
Mean ± standard deviation ΔCt levels of expression are given for each subcategory of FLT3-ITD/D835-negative AML. Levels of expression for positive cases are indicated in Figure 3.
FAB classification is restricted to the 168 AML 10 patients (FAB and karyotypic details were not available for 7 and 13 patients, respectively), whereas the cytogenetic classification (CG) also includes 9 DEK-CAN, 16 PML-RARA, and 48 non-AML 10 AML cases with MLL abnormalities, which were treated on a variety of different protocols.
Includes 2 AML1-ETO, 1 CBFβ-MYH11 in each FAB group.
Includes trisomies (+2, 8, 11, 21) and all other structural chromosomal translocations.
Includes one patient with CBFβ-MYH11 and MLL duplication and one inv(16) for which the type of CBFβ-MYH11 fusion transcript could not be identified.
Includes one 11-year-old child with hyperdiploid AML M1 (51, XY, +5, +6, +9, +10, +13).
Includes 3 MLL-AF10, 4 MLL-ELL.
Includes 4 MLL-AF9, 3 MLL-AF10, one unidentified t(9; 11).
Includes 3 t(9, 11), 2 t(11, 19), and one t(11,22).